Outside of direct theranostic applications, the role of hypoxia as a predictive and prognostic biomarker in patients with head and neck cancer suggests an important role for imaging of CAIX—i.e., that higher uptake of CAIX-targeted agents might be used to select appropriate therapeutic regimens and might also be negatively associated with patient outcomes. Here, CA9 is linked to head and neck cancer.